What the research found
GLP receptor agonists like retatrutide and semaglutide produce cold sensitivity in some users—a side effect the author attributes to three overlapping mechanisms rather than a single cause. The first involves concurrent loss of both fat and lean mass: as subcutaneous fat depletes, cold reaches deeper tissues more efficiently, while muscle loss reduces baseline heat production. The second is impaired thyroid hormone conversion: caloric deficit suppresses the hepatic and renal conversion of T4 to the active T3 form, a metabolic adaptation historically advantageous during famine but problematic during intentional weight loss. The third is suppression of the HPG axis, reducing testosterone in men and estrogen in women—both hormones contribute to thermoregulation.
The author notes that standard thyroid screening (TSH alone) often misses this pattern because TSH can remain normal while free T3 drops meaningfully. This represents a functional hypothyroid state that conventional clinic workflows may not detect.
Why it matters for you
If you're using a GLP and experiencing persistent cold intolerance despite normal TSH, ask your provider specifically for free T3 and free T4 alongside the basic panel. This is especially relevant if you're also tracking body composition and notice rapid fat loss or difficulty maintaining muscle—both amplify the thermal effect.
The practical implication is that cold sensitivity on GLP therapy isn't inevitable and doesn't require stopping the compound. Dose titration matters: starting lower (the author suggests 0.5 mg/week for retatrutide) and increasing gradually gives your metabolic and hormonal systems time to adapt. Resistance training becomes non-negotiable, not just for aesthetics but because muscle actively generates heat at rest. If you're tracking biomarkers, add free T3, testosterone or estradiol, and LH/FSH to your panel—these directly explain cold sensitivity and fatigue that might otherwise be attributed to the peptide itself or dismissed as normal weight-loss side effects.
Caveats
- Single-subject anecdote: This is the author's personal experience, not a systematic study.
- Mechanistic inference, not direct evidence: The three proposed mechanisms are plausible but inferred; the post doesn't cite controlled data demonstrating causality in GLP users.
- Uncontrolled setting: No dose quantification, training data, or dietary tracking provided for the author's own case.
- Self-prescribed compounds: Retatrutide is not approved by major regulatory agencies; dosing guidance is based on community reports rather than clinical trials.
- Incomplete labs baseline: The author didn't establish pre-GLP thyroid or hormone values, so the degree of suppression is unclear.